{"id":"https://openalex.org/W2797159595","doi":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","title":"Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily","display_name":"Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily","publication_year":2018,"publication_date":"2018-04-12","ids":{"openalex":"https://openalex.org/W2797159595","doi":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","mag":"2797159595","pmid":"https://pubmed.ncbi.nlm.nih.gov/29648839"},"language":"en","primary_location":{"id":"doi:10.1021/acs.molpharmaceut.7b01167","doi":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111475201","display_name":"Takako Niwa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takako Niwa","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112713472","display_name":"Yuji Kasuya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuji Kasuya","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105143964","display_name":"Yukie Suzuki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yukie Suzuki","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113758236","display_name":"Kimihisa Ichikawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kimihisa Ichikawa","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051881494","display_name":"Hiroko Yoshida","orcid":"https://orcid.org/0000-0002-1436-2315","observed_orcids":["https://orcid.org/0000-0002-1436-2315"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroko Yoshida","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034598788","display_name":"Akiko Kurimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akiko Kurimoto","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012194668","display_name":"Kento Tanaka","orcid":"https://orcid.org/0000-0002-8513-7748","observed_orcids":["https://orcid.org/0000-0002-8513-7748","https://orcid.org/0000-0002-3532-6954"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kento Tanaka","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083108371","display_name":"Koji Morita","orcid":"https://orcid.org/0000-0001-9353-4922","observed_orcids":["https://orcid.org/0000-0001-9353-4922"]},"institutions":[{"id":"https://openalex.org/I4210104626","display_name":"Daiichi-Sankyo (Japan)","ror":"https://ror.org/027y26122","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210104626"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Koji Morita","raw_affiliation_strings":["Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan"],"raw_orcid":"https://orcid.org/0000-0001-9353-4922","affiliations":[{"raw_affiliation_string":"Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan","institution_ids":["https://openalex.org/I4210104626"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5083108371"],"corresponding_institution_ids":["https://openalex.org/I4210104626"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.9366,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.7165855,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"15","issue":"9","first_page":"3729","last_page":"3740"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.5238999724388123,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.5238999724388123,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.22089999914169312,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.11330000311136246,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunoliposomes","display_name":"immunoliposomes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/agonistic-antibodies","display_name":"agonistic antibodies","score":0.9599999785423279},{"id":"https://openalex.org/keywords/tnf-receptor-superfamily","display_name":"TNF receptor superfamily","score":0.9179999828338623},{"id":"https://openalex.org/keywords/tra-8","display_name":"TRA-8","score":0.9010000228881836},{"id":"https://openalex.org/keywords/dr5","display_name":"DR5","score":0.9610000252723694},{"id":"https://openalex.org/keywords/trail","display_name":"TRAIL","score":0.7269999980926514},{"id":"https://openalex.org/keywords/apoptosis-induction","display_name":"apoptosis induction","score":0.7260000109672546},{"id":"https://openalex.org/keywords/fab-fragment","display_name":"Fab fragment","score":0.7099999785423279},{"id":"https://openalex.org/keywords/death-receptor-4","display_name":"death receptor 4","score":0.8019999861717224},{"id":"https://openalex.org/keywords/fas","display_name":"Fas","score":0.8040000200271606},{"id":"https://openalex.org/keywords/antibody-density","display_name":"antibody density","score":0.5440000295639038},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.5339999794960022},{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.6381216049194336},{"id":"https://openalex.org/C187898756","wikidata":"https://www.wikidata.org/wiki/Q395324","display_name":"Agonistic behaviour","level":3,"score":0.625786542892456},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4988229274749756},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.49638277292251587},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4955991506576538},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4783984422683716},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4722931683063507},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.44908446073532104},{"id":"https://openalex.org/C92028520","wikidata":"https://www.wikidata.org/wiki/Q7395025","display_name":"SUPERFAMILY","level":3,"score":0.4203639626502991},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32980623841285706},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2850476801395416},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.25349754095077515},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13410276174545288},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C2779448149","wikidata":"https://www.wikidata.org/wiki/Q191797","display_name":"Aggression","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000072283","descriptor_name":"A549 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018124","descriptor_name":"Receptors, Tumor Necrosis Factor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053220","descriptor_name":"Receptors, TNF-Related Apoptosis-Inducing Ligand","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053221","descriptor_name":"TNF-Related Apoptosis-Inducing Ligand","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/acs.molpharmaceut.7b01167","doi":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.molpharmaceut.7b01167","pdf_url":null,"source":{"id":"https://openalex.org/S204562082","display_name":"Molecular Pharmaceutics","issn_l":"1543-8384","issn":["1543-8384","1543-8392"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Pharmaceutics","raw_type":"journal-article"},{"id":"pmid:29648839","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29648839","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular pharmaceutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310431","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":58,"referenced_works":["https://openalex.org/W1484348104","https://openalex.org/W1514586505","https://openalex.org/W1560886923","https://openalex.org/W1599806854","https://openalex.org/W1710317859","https://openalex.org/W1936637282","https://openalex.org/W1964165239","https://openalex.org/W1964643758","https://openalex.org/W1972473939","https://openalex.org/W1973138068","https://openalex.org/W1973154591","https://openalex.org/W1976029952","https://openalex.org/W1986516374","https://openalex.org/W1986549286","https://openalex.org/W1994008624","https://openalex.org/W1996044226","https://openalex.org/W1998357686","https://openalex.org/W2009475191","https://openalex.org/W2009800901","https://openalex.org/W2012196034","https://openalex.org/W2017968389","https://openalex.org/W2023342930","https://openalex.org/W2024971144","https://openalex.org/W2033691661","https://openalex.org/W2033816932","https://openalex.org/W2035990435","https://openalex.org/W2045023657","https://openalex.org/W2049474922","https://openalex.org/W2050271125","https://openalex.org/W2050405684","https://openalex.org/W2055069207","https://openalex.org/W2057053889","https://openalex.org/W2059526131","https://openalex.org/W2062214897","https://openalex.org/W2063413426","https://openalex.org/W2078784708","https://openalex.org/W2086932069","https://openalex.org/W2088291142","https://openalex.org/W2098182642","https://openalex.org/W2100204192","https://openalex.org/W2102986716","https://openalex.org/W2106867787","https://openalex.org/W2107610558","https://openalex.org/W2117940906","https://openalex.org/W2119501278","https://openalex.org/W2119871165","https://openalex.org/W2119930182","https://openalex.org/W2158811570","https://openalex.org/W2159232758","https://openalex.org/W2161153456","https://openalex.org/W2166458266","https://openalex.org/W2171139000","https://openalex.org/W2301039287","https://openalex.org/W2395890656","https://openalex.org/W2576041594","https://openalex.org/W2609050738","https://openalex.org/W2609152985","https://openalex.org/W2620721016"],"related_works":["https://openalex.org/W1984758435","https://openalex.org/W2381615914","https://openalex.org/W2318663432","https://openalex.org/W2016516934","https://openalex.org/W2036495303","https://openalex.org/W2109463067","https://openalex.org/W3030389973","https://openalex.org/W4399326213","https://openalex.org/W2772407987","https://openalex.org/W2763910074"],"abstract_inverted_index":{"We":[0],"have":[1],"developed":[2],"a":[3,115,236,245,267],"technology":[4],"for":[5,202,209,248],"efficiently":[6],"enhancing":[7],"the":[8,16,24,37,49,57,68,95,124,135,140,145,148,153,158,165,176,184,220,261],"anticancer":[9],"apoptosis-inducing":[10,62,106,214],"activity":[11,107,133,173,205,243],"of":[12,26,70,92,123,134,142,183,219,251,260,264],"agonistic":[13,34,82,270],"antibodies":[14,35,63,143,215],"against":[15,84,108,190,216],"tumor":[17],"necrosis":[18],"factor":[19],"receptor":[20,86,226],"(TNFR)":[21],"superfamily":[22,39,269],"by":[23,43,72],"formation":[25],"immunoliposomes.":[27],"To":[28,60],"induce":[29],"apoptosis":[30],"in":[31],"cancer":[32],"cells,":[33,74,192],"to":[36,54],"TNFR":[38,221],"normally":[40],"need":[41],"cross-linking":[42,71,120],"internal":[44],"immune":[45,73],"effector":[46],"cells":[47,113],"via":[48],"Fc":[50],"region":[51],"after":[52],"binding":[53],"receptors":[55,218],"on":[56,94,144],"cell":[58],"membrane.":[59],"develop":[61],"that":[64,122,201,239],"do":[65],"not":[66,151],"require":[67],"support":[69],"we":[75],"prepared":[76],"immunoliposomes":[77,104,136,168,210,232],"conjugated":[78,211],"with":[79,89,139,175,212,256],"TRA-8,":[80],"an":[81,252],"antibody":[83,93,149,155,253],"death":[85,225],"5":[87],"(DR5),":[88],"various":[90,109],"densities":[91],"liposome":[96],"surface,":[97],"and":[98,127,164,229,255],"evaluated":[99],"their":[100],"activities.":[101],"The":[102,132],"TRA-8":[103,126,166,185],"exhibited":[105],"DR5-positive":[110],"human":[111,195],"carcinoma":[112],"at":[114,244],"significantly":[116],"lower":[117,199],"concentration":[118],"without":[119],"than":[121,200],"original":[125],"its":[128],"natural":[129],"ligand":[130],"(TRAIL).":[131],"was":[137,198,206],"correlated":[138],"density":[141],"surface.":[146],"As":[147],"component,":[150],"only":[152],"full-length":[154,186],"but":[156],"also":[157,169,207],"Fab'":[159,167,188],"fragment":[160,254],"could":[161,240],"be":[162],"used,":[163],"showed":[170],"exceedingly":[171],"high":[172],"compared":[174],"parental":[177],"antibody,":[178],"namely,":[179],"TRA-8.":[180],"Moreover,":[181],"cytotoxicity":[182],"or":[187],"immunoliposome":[189],"normal":[191],"such":[193,223],"as":[194,224,235,266],"primary":[196],"hepatocytes,":[197],"TRAIL.":[203],"Enhanced":[204],"observed":[208],"other":[213,217],"superfamily,":[222],"4":[227],"(DR4)":[228],"Fas.":[230],"Thus,":[231],"are":[233],"promising":[234],"new":[237],"modality":[238],"exhibit":[241],"significant":[242],"low":[246],"dose,":[247],"cost-effective":[249],"application":[250],"stable":[257],"efficacy":[258],"independent":[259],"intratumoral":[262],"environment":[263],"patients":[265],"TNF":[268],"therapy.":[271]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-04-24T00:00:00"}